BNTC · sample dossier
Benitec Biopharma Inc. Common Stock
34/100
OutdatedGenerated Sep 19, 2026 · 10:00 AM UTC · 48 days ago
This copy is frozen (Sep 19). Sign in to run the same work — filings, valuation, bull and bear, sources — on any US stock or ETF, in about 90 seconds.
Run a fresh dossierBNTC
EquityBenitec Biopharma Inc. Common Stock · XNAS
Decision context
Recommendation
Weighed down by weak Quality (13/100) and Momentum (13/100) scores.
A cautious picture — if you own it, consider taking some off.
AlphaDog Fair Value
Executive thesis & key metrics
Executive Investment Thesis
Benitec Biopharma Inc. is a clinical-stage biotechnology company with a market capitalization of $384.41M, trading at a price-to-book ratio of 2.14 and an EV/EBITDA multiple of -4.01. A Reduce posture is justified by negative operating efficiency with a return on assets of -22.7%-$0.48 (four-quarter statements divided by shares outstanding) free cash flow per share of -$0.08, and revenue growth that is Not publicly available despite zero debt with Debt/Equity at 0.00. The single biggest risk is aggressive equity dilution of +32.6% YoY alongside a Piotroski F-Score of 3/9 and an ongoing 1-year price drawdown of -19.6%.
Key Metrics to Watch
What changed recently
No material changes found in the last 30 days.
Why this rating
Score 34 · Sell
Data through
OutdatedJun 30, 2026
Composite 34/100 — weak across most factors.
Levels unavailable — AlphaDog quantitative valuation model did not produce an estimate from comps or DCF
Re-evaluate if
- Severe accounting disclosures (auditor / restatement / going concern) in SEC filings
- Net margin falls below 0.0% (was 0.0%)
- Debt/Equity ratio increases above 0.00.
Trim / reconsider if
- ROA deteriorates below -22.7%
- Debt/Equity ratio increases above 0.00.
Think of these dollars as a map of our value estimate for Sell — helpful context, not a reason to override the view.
A Calmer Look · Devil's Advocate
The consensus recommendation to Reduce Benitec Biopharma leans disproportionately on backward-looking forensic ratios that mischaracterize a clinical-stage development biotech as a failing operating business.
May be overlooked
Consensus fixates on an 8-K non-reliance restatement filed on 2025-09-12, ignoring that the filing is over 370 days stale and has been succeeded by clean regulatory filings through 2026-09-14.
The scoring engine heavily penalizes the Piotroski F-Score at 3/9 and EV/EBITDA of -4.01, applying traditional industrial efficiency metrics to a pre-revenue pipeline biotech that structurally cannot produce positive operating income.
The debate omits clinical pipeline progression entirely, failing to evaluate binary milestone risks or catalysts for BB-301 while pricing the equity purely on accounting liquidation metrics.
Expectations look stretched
The bull case relies on a Price/Book multiple of 2.14 as balance sheet support, ignoring that book value in pre-commercial biotech rapidly erodes with ongoing cash burn at $-0.08 FCF per share.
Headline sentiment tracking 8 positive and 0 negative articles is overly optimistic and detached from price action, with shares down -17.6% over 1 month and trading below both MA50 and MA200.
Bull arguments lean on institutional insider stakes from December 2025 totaling $187,592, which are over 260 days stale and represent negligible fractional ownership (<0.10%).
Gross margin falls below 0.0% due to manufacturing cost recognition.
Gross margin falls below 0.0% due to manufacturing cost recognition.
Monitor These Triggers
3 Checkpoints · Next PrintFree cash flow per share (baseline: $-0.08) to measure quarterly cash burn rate.
Market context
Snapshot returns at report publication
1 month
-17.6%
3 months
-9.3%
6 months
-4.2%
1 year
-19.6%
At a Glance
A smaller company is in a pullback at unprofitable earnings.
Top Holders
Financial trajectory
Financial Performance
Go deeper
For learning and research only — not investment advice. AlphaDog doesn’t hold stocks and isn’t your financial advisor.
Run the next one yourself.
You just read a full BNTC dossier — scored verdict, valuation, and both sides, with sources. Sign in to run that on a name you hold, on current filings. A free account includes 10 credits a week, 1 per fresh run.